Processa Pharmaceuticals, Inc. (PCSA)
| Market Cap | 5.50M -48.6% |
| Revenue (ttm) | n/a |
| Net Income | -13.44M |
| EPS | -5.59 |
| Shares Out | 3.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 84,164 |
| Open | 1.830 |
| Previous Close | 1.760 |
| Day's Range | 1.570 - 1.848 |
| 52-Week Range | 1.570 - 14.243 |
| Beta | 0.97 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About PCSA
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metasta... [Read more]
Financial Performance
Financial StatementsNews
Processa Pharmaceuticals Slides: Corporate presentation
Processa Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 17, 2026.
Processa Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A major acquisition and $200 million financing enable parallel phase II development of a differentiated BTK inhibitor for food allergy, CSU, and relapsing MS, with initial data expected in 2027–2028. Strong phase I data support once-daily dosing and a favorable safety profile.
Processa Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
A recent merger and $200M PIPE have positioned the company to advance VT-7208, a next-gen BTK inhibitor, into three phase II trials targeting food allergy, CSU, and relapsing MS. Early data show strong safety, CNS penetration, and durable target engagement. VT-7208 aims to outperform competitors with once-daily dosing and a favorable safety profile.
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
VERO BEACH, FL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor...
Processa Pharmaceuticals Quarterly report: Q2 2026
Processa Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
Processa buys Vidya Therapeutics, raises $200 million for drug trials
Processa Pharmaceuticals said on Wednesday it acquired privately held Vidya Therapeutics in an all-stock deal, gaining access to its lead candidate being developed to target diseases involving the i...
Processa Pharmaceuticals Transcript: M&A announcement
The acquisition adds a differentiated BTK inhibitor to the pipeline, enabling parallel development in food allergy, CSU, and MS, funded by $200M in new financing. Phase II studies are set to begin in 2026, targeting large unmet needs with a once-daily oral therapy.
Processa Pharmaceuticals Press release: M&A announcement
Processa Pharmaceuticals issued a press release on July 29, 2026, disclosing material business information to investors.
Processa Pharmaceuticals Slides: M&A announcement
Processa Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 29, 2026.
Processa Pharmaceuticals acquires Vidya Therapeutics in stock-for-stock deal
Processa Pharmaceuticals (PCSA) announced it has acquired Vidya Therapeutics. Concurrent with the acquisition, Processa entered into a definitive agreement for a private placement financing expected t...
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC.
Acquisition brings into Processa's pipeline Vidya's lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton's tyrosine kinase inhibitor (BTKi) designed...
Processa Pharmaceuticals Proxy statement: Proxy filing
Processa Pharmaceuticals filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Processa Pharmaceuticals Quarterly report: Q1 2026
Processa Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Processa Pharmaceuticals Annual report: Q4 2025
Processa Pharmaceuticals has published its Q4 2025 annual report on March 18, 2026.
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today a...
Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluatin...
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company deve...
Here’s Why Penny Stock Processa Pharmaceuticals (PCSA) Is Exploding Today
Penny stock Processa Pharmaceuticals ($PCSA) surged as much as 130% on Wednesday. The upside is due to encouraging preliminary data from its ongoing Phase 2 study evaluating next-generation cancer the...
Processa Pharmaceuticals provides update on Phase 2 NGS-Cap
Processa Pharmaceuticals (PCSA) provided a clinical update on its ongoing Phase 2 study of NGC-Cap, the combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breas...
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine
Processa Pharmaceuticals Inc trading halted, news pending
19:50 EST Processa Pharmaceuticals (PCSA) Inc trading halted, news pending
Processa Pharmaceuticals Quarterly report: Q3 2025
Processa Pharmaceuticals has published its Q3 2025 quarterly earnings report on November 6, 2025.
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and inno...
Processa Pharmaceuticals price target lowered to $1 from $2 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Processa Pharmaceuticals (PCSA) to $1 from $2 and keeps a Buy rating on the shares. The firm cites equity…
Processa Pharmaceuticals Proxy statement: Proxy Filing
Processa Pharmaceuticals filed a proxy statement on August 25, 2025, providing details for shareholder voting and corporate governance matters.